Achilles Therapeutics (ACHL)
NASDAQ: ACHL
· Real-Time Price · USD
1.48
0.00 (0.00%)
At close: Mar 20, 2025, 3:59 PM
Achilles Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -47.66M | -47.66M | -52.9M | -58.35M | -54.13M | -71.4M | -71.25M | -65.24M | -65.82M | -64.69M | -61.1M | -55.79M | -42.85M | -26.7M |
Depreciation & Amortization | 4.71M | 3.54M | 3.46M | 3.14M | 2.84M | 3.75M | 3.7M | 3.7M | 3.64M | 3.55M | 3.29M | 2.85M | 2.02M | 1.19M |
Stock-Based Compensation | 4.1M | 2.79M | 3.05M | 3.34M | 4.99M | 6.71M | 7.02M | 7.1M | 7.18M | 6.89M | 6.32M | 6.39M | 4.66M | 3.22M |
Other Working Capital | 9.24M | 9.24M | 17.1M | 12.87M | 3.47M | -1.5M | -7.91M | -5.81M | -6.18M | -10.13M | -5.36M | -8.36M | -13.48M | -4.54M |
Other Non-Cash Items | -8.36M | 11.44M | 7.56M | 13.94M | 13.42M | 13.86M | 13.61M | 3.37M | -368K | -921K | -18K | 537K | 832.01K | 945.83K |
Deferred Income Tax | -6.11M | -6.11M | -6.11M | -5.76M | -6.8M | -6.8M | -6.8M | -3.28M | 159K | 159K | 159K | 4K | n/a | n/a |
Change in Working Capital | 9.09M | 9.09M | 13.9M | 7.15M | -887.03K | -3.08M | -6M | 63.45K | -5.21M | -7.69M | -7.93M | -7.35M | -8.92M | -4.25M |
Operating Cash Flow | -47.98M | -30.66M | -31.02M | -36.52M | -40.55M | -56.94M | -59.72M | -54.29M | -60.43M | -62.7M | -59.28M | -53.35M | -44.26M | -25.59M |
Capital Expenditures | -801.63K | -802.13K | -561.53K | -2.58M | -4.39M | -6.12M | -7.53M | -7.46M | -6.82M | -7.12M | -7.63M | -11.61M | -10.4M | -8.36M |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -35.96K | n/a | n/a | -7.51M | -7.51M | -7.51M | -7.51M | -7.63M | -7.63M | -7.63M | -7.63M | n/a | n/a | n/a |
Investing Cash Flow | -837.59K | -802.13K | -561.53K | -2.58M | -4.39M | -6.12M | -7.53M | -7.46M | -6.82M | -7.12M | -7.63M | -11.61M | -10.4M | -8.36M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 2.86 | 2.86 | 1K | 1K | 1.01K | 1.01K | 10.29 | 60.01K | 60K | 161.67M | 160.75M | 274.6M | 303.02M | 169.84M |
Financial Cash Flow | 13.03K | 13.03K | 8.03K | 8.04K | 999.38 | 999.38 | 999.38 | -388.59K | -389.52K | -227.91K | -228.83K | 114.06M | 142.49M | 170.75M |
Net Cash Flow | -48.58M | -31.4M | -27.06M | -25.02M | -43.15M | -78.47M | -92.98M | -101.98M | -97.69M | 77.7M | 88.5M | 210.31M | 227.71M | 87.65M |
Free Cash Flow | -31.47M | -31.47M | -31.58M | -39.1M | -44.94M | -63.06M | -67.25M | -61.76M | -67.25M | -69.82M | -66.92M | -64.97M | -54.66M | -33.95M |